The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identifying targeted therapy combination for refractory colorectal cancer using micro-organospheres.
 
Shengli Ding
Stock and Other Ownership Interests - Xilis
 
Preeti Kanikarla Marie
No Relationships to Disclose
 
Ray Zhang
Employment - Xilis
Consulting or Advisory Role - Xilis
Travel, Accommodations, Expenses - xilis
 
Nicholas Baro
No Relationships to Disclose
 
Daniel W Brown
Employment - Xilis
Research Funding - Xilis (Inst)
 
Alan Bohn
Employment - Regeneron; Xilis
Stock and Other Ownership Interests - 10X Genomics; 10X Genomics; InVitae
Research Funding - Xilis (Inst)
 
Kelly Pittman
Stock and Other Ownership Interests - Xilis
 
Marcin Paduch
Employment - ArsenalBio; Xilis
Stock and Other Ownership Interests - ArsenalBio (I); Illumina (I)
Patents, Royalties, Other Intellectual Property - I'm receiving royalties through Polsky Center technology transfer office for the collection of therapeutic assets licensed to major pharmaceutical companies.
 
Shiaowen David Hsu
Stock and Other Ownership Interests - Accubeing; Xilis
Research Funding - Amgen
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Servier; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Xiling Shen
Employment - Xilis
Leadership - Xilis
Stock and Other Ownership Interests - Xilis
Patents, Royalties, Other Intellectual Property - Xilis
Travel, Accommodations, Expenses - Xilis